Labcorp announced the launch of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA molecular residual disease solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy. This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp ,Xcell Biosciences deepen tie-up, adding new elements to collaboration
- Labcorp Announces Acquisition of Select Assets of BioReference Health’s Diagnostics Business
- Labcorp to acquire select assets of BioReference Health for $237.5M
- Labcorp Announces Q1 2024 Earnings Call and Webcast
- Tesla downgraded, Disney upgraded: Wall Street’s top analyst calls